Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01

IRVINE, Calif., Jan. 18, 2024.  PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials